Does Rallies show 13F holders for DRUG?

Yes. Rallies tracks hedge fund and 13F ownership data for DRUG, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DRUG research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DRUG. It does not provide personalized investment advice.

DRUG (Bright Minds Biosciences Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Bright Minds Biosciences Inc. Common Stock (DRUG) is a publicly traded Healthcare sector company. As of May 21, 2026, DRUG trades at $83.00 with a market cap of $734.04M and a P/E ratio of 0.00. DRUG moved +11.07% today. Year to date, DRUG is +3.46%; over the trailing twelve months it is +155.02%. Its 52-week range spans $0.94 to $123.75. Analyst consensus is strong buy with an average price target of $145.67. Rallies surfaces DRUG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DRUG stock?

Hedge funds tracked by Rallies that own DRUG include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bright Minds Biosciences Inc. Common Stock.

DRUG Key Metrics

Key financial metrics for DRUG
Metric	Value
Price	$83.00
Market Cap	$734.04M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$123.75
52-Week Low	$0.94
Volume	41
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding DRUG

Orbimed Advisors holds 40.00K shares of DRUG, changed +0.00% as of Mar 31, 2026.

Latest DRUG News

Helus HLP004 Phase 2 Posts 10.4-Point HAM-A Gain; BPL-003 Phase 3 Wins FDA Nod — Mar 6, 2026
Bright Minds Price Target Falls to $126, BMB-101 Cuts Seizures Over 60% — Feb 19, 2026
Canadian Securities Exchange Records 2.0 Billion Shares and $446 Million Financing in January — Feb 17, 2026
Bright Minds Biosciences Raises $175M via 1.945M Share Offering at $90 — Jan 9, 2026
Bright Minds Biosciences’ BMB-101 Cuts Absence Seizures by 73% and Boosts REM Sleep 90% — Jan 8, 2026

Recent DRUG Insider Trades

Cormorant Asset Management, LP sold 109.33K (~$9.79M) on Apr 28, 2026.
Cormorant Asset Management, LP bought 184.33K (~$4.00M) on Nov 4, 2024.
Cormorant Asset Management, LP bought 39.74K (~$922.63K) on Oct 16, 2024.

DRUG Analyst Consensus

3 analysts cover DRUG: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $145.67.

Common questions about DRUG

Who owns DRUG stock?: Hedge funds tracked by Rallies that own DRUG include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bright Minds Biosciences Inc. Common Stock.
Does Rallies show 13F holders for DRUG?: Yes. Rallies tracks hedge fund and 13F ownership data for DRUG, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DRUG research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DRUG. It does not provide personalized investment advice.